FOLH1 and prostate carcinoma: The PSMA binding affinities were determined in a competitive binding assay using LNCaP human prostate carcinoma cells and the known high affinity PSMA ligand ([125I]I-BA)KuE [10] (c = 0.2 nM) as the radioligand.